conference Archives - Page 7 of 13

Dr Zhu Yao’s Team: Significant Survival Differences in Newly Diagnosed mPC Patients between Asian and Caucasian patients, International Clinical Trial Designs Should Consider This Factor

By Peng Geng 2023.10.13

Are there differences in long-term prognosis between Asian and Caucasian patients with new metastatic prostate cancer (mPC)? A study presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) by Dr. Zhu Yao's team suggests that among patients receiving different treatment regimens, Asian males have superior overall survival (OS) and cancer-specific survival (CSS) compared to white males in this category. This research highlights the importance of considering Asians as an independent prognostic factor when evaluating individual patient outcomes and the need to include an adequate representation of Asian patients in the design of global multicenter clinical trials.

Comprehensive Research from West China Hospital of Sichuan University

By Peng Geng 2023.10.13

The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU 2023) was held in San Francisco, USA, from February 16th to 18th, 2023. Dr. Qiang Wei and Dr. Hao Zeng's team had multiple findings selected for academic exchange at this ASCO-GU symposium. Their work addressed prostate cancer, urinary tract carcinoma, and kidney cancer, covering prospective clinical trials, retrospective studies, and translational research. They shared and conveyed the "West China Experience" and "West China Plan" on the international stage.

Dr. Bo Dai: Research Progress in ASCO-GU 2023 prostate cancer

By Peng Geng 2023.10.13

The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium for 2023 (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. Numerous innovative treatment studies have emerged in the fields of metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and early/localized prostate cancer. These studies encompass a wide range of therapies, including androgen deprivation therapy (ADT), novel hormonal therapy (NHT), PARP inhibitors (PARPi), immunotherapy, nuclear medicine therapy, and localized treatments.

Dr. Huichuan Sun: Focusing on the Asia-Pacific Region, Leading the Frontier – Exploring Breakthroughs in the Treatment of Hepatobiliary Tumor

By Lynn 2023.10.13

The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) recently concluded in Seoul, South Korea, bringing together top experts in liver and biliary system tumors from around the world to discuss clinical hot topics and challenges. Dr. Huichuan Sun from Zhongshan Hospital, Fudan University, China, shares and interprets the latest developments and frontiers, including the Asia-Pacific consensus and groundbreaking research with us.

Dr. Zhaochong Zeng: Enhancing Efficiency and Reducing Burden – Latest Advances in Radiotherapy for Liver Cancer Treatment

By Lynn 2023.10.13

Stereotactic Body Radiotherapy (SBRT), as a novel radiotherapy technique, has achieved encouraging results in the treatment of liver cancer. It not only improves local tumor control but also reduces distant metastases caused by tumors. Additionally, it minimizes radiation therapy-related complications, enhancing the quality of life for patients after treatment. However, how to maximize the role of SBRT in comprehensive liver cancer treatment is a topic worthy of further exploration. At the 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023), Dr. Zhaochong Zeng and his team from Zhongshan Hospital, Fudan University, China, presented two studies selected for oral and poster presentations, focusing on improving the effectiveness of SBRT and reducing radiation therapy-related adverse reactions, which attracted significant attention at the conference. In this article, Dr. Zeng shares insights into these two studies.

Congratulations! Dr. Jian Zhou has been elected as the President-elect of the Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE)

By Lynn 2023.10.13

From July 6th to 8th, 2023, the 13th annual meeting of the Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE) was held in Seoul, South Korea, with the participation of nearly 1000 experts and scholars in the field of liver cancer from around the world.

Dr. Gong Li: Combined Radiotherapy, Anti-Angiogenic Medication, and Immunotherapy for Downstaging Treatment in Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombus

By Lynn 2023.10.13

Hepatocellular carcinoma (HCC) is one of the most common malignancies in China, with most patients diagnosed in the intermediate to advanced stages. The formation of portal vein tumor thrombus (PVTT) is a critical indicator of HCC progression, and patients with HCC combined with PVTT have a very poor prognosis. Previous studies have shown that low-dose radiotherapy can extend the survival of HCC patients with PVTT. From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) was held in Seoul, South Korea. At the conference, a team led by Academician Jiahong Dong, Dr. Gong Li, and Dr. Keran Li from Beijing Tsinghua Chang Gung Hospital, Tsinghua University, China, presented a clinical study (Abstract Number: PE-97), investigating whether PVTT is more sensitive to radiotherapy than the primary tumor and exploring the efficacy of downstaging treatment in HCC patients with PVTT through the combination of radiotherapy, anti-angiogenic medication, and immunotherapy. Hepatology Digest had the privilege of inviting Dr. Gong Li to share the results of this research and its clinical application prospects.

Dr.Wai-Kay Seto: Balancing the Risks and Benefits of Long-Term HBV Treatment

By Lynn 2023.10.13

The World Health Organization (WHO) has set ambitious goals in its Action Plan for the Elimination of Viral Hepatitis: by 2030, the diagnosis rate for chronic hepatitis B (CHB) should reach 90%, the treatment rate for eligible patients should be 80%, new infections should decrease by 90%, and related deaths should decrease by 65%. However, recent data shows that in mainland China and Hong Kong, the diagnosis rates for CHB are only 19% and 27%, respectively, and the treatment rates are only 11% and 22%, respectively. Globally, the diagnosis and treatment rates for CHB are only 10% and 5%, respectively. Achieving WHO's 2030 goal of eliminating viral hepatitis as a public health threat remains a daunting challenge. At the 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023), Dr. Wai-Kay Seto from the University of Hong Kong, China, was invited to give a special report on the risks and benefits of long-term HBV treatment.

Dr. Masatoshi Kudo: Does the Treatment Paradigm for Intermediate HCC Need to Change?

By Lynn 2023.10.13

In recent years, there has been rapid progress in the systemic treatment of liver cancer, with new immunotherapies and targeted therapies continually emerging. This has also driven ongoing innovation in the concepts and approaches for treating HCC. From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Experts Conference (APPLE 2023) was held in Seoul, South Korea. During the conference, one of the founders of APPLE, Dr. Masatoshi Kudo from Kindai University in Japan, shared the latest research developments in systemic treatment for intermediate HCC and its potential applications. Hepatology Digest had the privilege of conducting an in-depth interview with Dr. Kudo at the APPLE conference. Here, we present the contents of that interview for our readers.

Dr. Kathryn J. Fowler: When to Consider Biopsy – Radiologist’s Perspective

By Lynn 2023.10.13

The diagnosis of liver cancer involves three aspects, including imaging, blood test results, and biopsy pathology results. Typically, the diagnosis of a tumor is confirmed only under a microscope after obtaining pathological tissue. However, liver cancer has its unique characteristics, and its diagnosis can be based on cirrhosis and confirmed through imaging tests such as computer tomography scans and magnetic resonance imaging. At the recently concluded 13th Asia-Pacific Primary Liver Cancer Expert Conference (APPLE 2023), Dr. Kathryn J. Fowler from the University of California, San Diego, shared insights from the perspective of a radiologist on the effectiveness and reliability of liver cancer imaging in clinical diagnosis, as well as the positive role of imaging in the classification and prognosis prediction of liver cancer patients. Hepatology Digest had the privilege of conducting an in-depth interview with Dr. Fowler at the conference, and we have compiled the content for our readers.